Thresholds of incremental cost (I$) per vaccinated girl associated with the 9-valent vaccine in Kenya and Uganda (discounting rate = 3% per year)^*.

* GDP = gross domestic product; I$ = international dollars. Values represent the added cost of the 9-valent HPV vaccine at which the incremental cost-effectiveness ratio (compared to current 2- or 4-valent vaccines) would be equal to 1x or 3x per capita GDP in each country. † Base case scenario = some benefits to prevent cervical cancer with unidentifiable types and multiple infections, defined as a function of the prevalence of the five targeted HPV types relative to the prevalence of all non-16/18 types, with 37.4% cross-protection against non-vaccine types. Thresholds of incremental cost (I$) per vaccinated girl associated with the 9-valent vaccine in Kenya and Uganda (discounting rate = 3% per year)*.